ZIOPHARM Oncology Inc (ZIOP) Upgraded by Zacks Investment Research to “Buy”

Zacks Investment Research upgraded shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) from a hold rating to a buy rating in a research report sent to investors on Friday. They currently have $5.25 price target on the biotechnology company’s stock.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

Several other analysts also recently weighed in on ZIOP. ValuEngine raised shares of ZIOPHARM Oncology from a sell rating to a hold rating in a research report on Monday, July 17th. HC Wainwright set a $10.00 target price on shares of ZIOPHARM Oncology and gave the stock a buy rating in a research report on Tuesday, August 1st. Finally, BidaskClub raised shares of ZIOPHARM Oncology from a sell rating to a hold rating in a research report on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. ZIOPHARM Oncology presently has a consensus rating of Hold and a consensus price target of $12.58.

ZIOPHARM Oncology (NASDAQ ZIOP) traded down $0.25 during trading hours on Friday, reaching $4.30. 3,309,900 shares of the company’s stock traded hands, compared to its average volume of 1,335,318. ZIOPHARM Oncology has a 12 month low of $4.16 and a 12 month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.11) EPS. equities analysts expect that ZIOPHARM Oncology will post -0.54 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/11/ziopharm-oncology-inc-ziop-upgraded-by-zacks-investment-research-to-buy.html.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper acquired 6,440 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $4.68 per share, with a total value of $30,139.20. Following the acquisition, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at $5,071,861.08. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 10.40% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in ZIOP. UBS Asset Management Americas Inc. boosted its holdings in shares of ZIOPHARM Oncology by 79.6% in the 1st quarter. UBS Asset Management Americas Inc. now owns 37,687 shares of the biotechnology company’s stock valued at $239,000 after acquiring an additional 16,700 shares during the last quarter. Parametric Portfolio Associates LLC lifted its stake in shares of ZIOPHARM Oncology by 325.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 81,011 shares of the biotechnology company’s stock valued at $514,000 after purchasing an additional 61,979 shares during the period. American International Group Inc. lifted its stake in shares of ZIOPHARM Oncology by 7.1% in the 1st quarter. American International Group Inc. now owns 74,843 shares of the biotechnology company’s stock valued at $475,000 after purchasing an additional 4,951 shares during the period. Teachers Advisors LLC lifted its stake in shares of ZIOPHARM Oncology by 8.3% in the 1st quarter. Teachers Advisors LLC now owns 214,906 shares of the biotechnology company’s stock valued at $1,363,000 after purchasing an additional 16,398 shares during the period. Finally, California Public Employees Retirement System lifted its stake in shares of ZIOPHARM Oncology by 95.9% in the 1st quarter. California Public Employees Retirement System now owns 435,532 shares of the biotechnology company’s stock valued at $2,541,000 after purchasing an additional 213,166 shares during the period. 41.86% of the stock is currently owned by institutional investors and hedge funds.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply